Table 1.

Participant demographics.

	WWH (N = 256)	HIV-negative (N = 206)	P-value
Age, years	34.5 [25.5–41.1] (12.0–49.3)	32.3 [24.8–41.9] (12.3–49.9)	0.62
Relative LTL	7.2 [6.4–7.9] (4.7–10.5)	7.5 [6.9–8.3] (5.3–11.3)	0.0002
AMH, ng/ml	1.5 [0.6–3.4] (0.0–85.0)	2.3 [0.5–4.7] (0.0–31.6)	0.032
Amenorrhea (N = 452)			0.86
Yes	37 (15)	29 (14)
No	212 (85)	174 (86)
BMI, kg/m2 (N = 441)	24.0 [21.4–28.6] (15.0–46.5)	22.9 [20.6–27.5] (14.0–47.6)	0.067
Ethnicity (N = 456)			<0.0001
Indigenous	59 (23)	53 (26)
Asian/Southeast Asian	21 (8)	30 (15)
African/Caribbean/Black	72 (29)	21 (10)
White	95 (38)	91 (45)
Other	5 (2)	9 (4)
Household Income (N = 378)			0.015
<$15 000/year	104 (53)	73 (40)
>$15 000/year	93 (47)	108 (60)
Education (N = 378)			<0.0001
Grade school	9 (5)	4 (2)
Some high school	62 (32)	37 (20)
High school graduate	46 (23)	18 (10)
Any college	77 (39)	121 (66)
Other	2 (1)	2 (1)
Tobacco smoking (N = 459)			<0.0001
Never	113 (44)	130 (64)
Past	27 (11)	25 (12)
Current	115 (45)	49 (24)
Current opioid (N = 426)			<0.0001
Yes	67 (28)	20 (11)
No	172 (72)	167 (89)
Detectable HIV VL (N = 250)
Yes	106 (42)
No	144 (58)
HIV peak VL >100 000 copies/ml (N = 253)
Yes	117 (46)
No	136 (54)
Perinatal HIV acquisition (N = 249)
Yes	49 (20)
No	200 (80)
On ART at visit (N = 240)
Yes	182 (76)
No	58 (24)

Data are presented as number (%) of individuals or median [interquartile range] (range). Number of participants with available data are indicated when applicable. Comparisons were done using chi-squared or Mann–Whitney U tests. Opioid use includes any prescribed or illicit use.

AMH, anti-Müllerian hormone; AR, antiretroviral therapy; BMI, body mass index; LTL, leukocyte telomere length; VL, viral load; WWH, women with HIV.